Bristol-Myers Squibb Co
XHAM:BRM

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
XHAM:BRM
Watchlist
Price: 48.05 EUR -0.16%
Market Cap: 106.7B EUR

Operating Margin

33.5%
Current
Improving
by 7.9%
vs 3-y average of 25.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.5%
=
Operating Income
$16.1B
/
Revenue
$48B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.5%
=
Operating Income
€16.1B
/
Revenue
$48B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Bristol-Myers Squibb Co
NYSE:BMY
112.5B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.8B GBP
Loading...
CH
Novartis AG
SIX:NOVN
222.2B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.5B AUD
Loading...
No Stocks Found

Market Distribution

Higher than 92% of companies in the United States of America
Percentile
92st
Based on 14 112 companies
92st percentile
33.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Bristol-Myers Squibb Co
Glance View

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BRM Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
33.5%
=
Operating Income
$16.1B
/
Revenue
$48B
What is Bristol-Myers Squibb Co's current Operating Margin?

The current Operating Margin for Bristol-Myers Squibb Co is 33.5%, which is above its 3-year median of 25.6%.

How has Operating Margin changed over time?

Over the last 3 years, Bristol-Myers Squibb Co’s Operating Margin has increased from 25.5% to 33.5%. During this period, it reached a low of 23.2% on Mar 31, 2024 and a high of 33.5% on Sep 30, 2025.

Back to Top